The fifth batch of collective procurement quotations finally settled. Judging from the quotation results, this quotation is very exciting. Rivaroxaban did not let it take the lead in the decline (a decrease of -99%). Oral preparations or injections continue the previous overall style, and most of them still don't participate.

There are pictures and the truth, the quotation details of each product and each company are as follows;

(Information source: The fifth batch of national procurement quotations site Fengyun Yaotan exclusive collation)

Special note: All information is subject to the official announcement!!!

Remarks: In order to avoid misunderstandings in data sharing, this article is not allowed to be reprinted!!! This article is not allowed to be reprinted!!! This article is not allowed to be reprinted!!!

Fengyun Brief Comment:

1. The competition is extremely fierce: By the day before the quotation on June 22, many products have been approved, cefuroxime from 3/4 to 4/5, ceftriaxone from 8/10 to 10/N, etc. This quotation was reviewed and reviewed the day before, which added a lot of bright and exciting features to the fifth batch of Guocai.

2. Highlights: Rivaroxaban has a minimum drop of 98%+. Products such as lipoic acid were only announced on the 23rd, and many products were approved on the 22nd. There were problems that have not been encountered before the price difference between dosage forms and specifications, as well as the original product research. Those who did not come to participate, the problems encountered in the fifth batch are the sum of the previous batches, and the weather in Shanghai today is particularly good, hahaha!!!

3. The decline is still sharp: Rivaroxaban, esomeprazole, docetaxel, palonosetron, and ceftriaxone dominate in terms of decline.

4. There are some products that focus on: budesonide, cefuroxime, cefazolin, fluconazole, cisatracurium, bicalutamide, dabigatran etexilate (similar spelling is almost the same) lipoic acid, etc. Products will still shine in the market!

The fifth batch of national procurement has new areas worthy of consideration and research in many aspects, such as price limit, changes in the competitive landscape, changes in the time of reporting to quotation, changes in bidding styles of domestic enterprises, and changes in bidding styles of foreign companies.

Congratulations to the enterprises of "Golden List Title"!!!